Cocrystal Pharma, Inc. COCP

Cocrystal Pharma reports potential breakthrough in norovirus antiviral development. Norovirus program advance could materially shift COCP pipeline value and investor focus.

Cocrystal Pharma appoints new CEO to lead norovirus treatment development efforts. New CEO appointment targets advancement of norovirus program with moderate potential to influence strategy and sentiment.

Cocrystal Pharma, Inc. has completed a registered direct offering of up to $13 million, priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing development efforts. The offering provides additional capital that may support future operations and initiatives.

Cocrystal Pharma dosed the final subject in its Phase 1b human challenge study of CDI-988 for norovirus prevention and treatment. Phase 1b completion marks incremental progress in norovirus antiviral development with moderate potential to influence pipeline momentum.

Cocrystal Pharma is executing a strategic reset with potential effects on its operations, pipeline and market positioning that investors may have overlooked. Strategic reset represents major move likely to alter company trajectory and investor views.

Cocrystal Pharma raises $5 million via private placement with OPKO Health. Private placement adds capital that can support operations and affect near-term financial position.

Cocrystal Pharma appoints James Sapirstein as chief executive officer. Sapirstein is a biopharma industry leader with extensive antiviral development experience. CEO appointment with antiviral expertise may moderately shape company strategy and operations.

Cocrystal Pharma presented highlights on CDI-988 development progress. CDI-988 presentation may moderately shift pipeline perceptions and near-term sentiment.

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting Hantavirus, Bunyavirus and Influenza. Pan-viral inhibitor discovery opens new revenue streams and strengthens competitive position in antiviral market.

Cocrystal Pharma, Inc. (COCP) provided a business update and reported first quarter 2026 financial results. Quarterly financial results and business updates moderately affect financial performance and investor sentiment.

Cocrystal Pharma presented at ICAR 2026, highlighting the mechanism of action and clinical advancement of CDI-988 for preventing and treating norovirus infection. Clinical advancement presentation for norovirus drug CDI-988 may positively influence investor sentiment and competitive positioning in antiviral space.

Cocrystal Pharma, Inc. (COCP) receives FDA Fast Track Designation for CDI-988, accelerating development and review for norovirus infection treatment and prevention amid no approved therapies. Fast Track Designation speeds CDI-988 development for unmet norovirus need, elevating COCP pipeline value and investor sentiment.

Cocrystal Pharma, Inc. (COCP) received FDA Fast Track Designation for CDI-988, its investigational drug for treating and preventing Norovirus infections. FDA Fast Track Designation expedites CDI-988 development for Norovirus, enhancing Cocrystal Pharma's pipeline value and market prospects.

Cocrystal Pharma, Inc. (COCP) reported 2025 financial results and provided updates on its antiviral drug-development programs. Financial results and antiviral program updates affect key areas like financial performance and product innovation with moderate influence.

Cocrystal Pharma dosed the first subjects in its Phase 1b clinical study evaluating CDI-988 for norovirus prevention and treatment. First dosing in Phase 1b trial marks a major clinical milestone for CDI-988, advancing Cocrystal Pharma's antiviral pipeline and likely boosting investor sentiment.

Cocrystal Pharma, Inc. has received Institutional Review Board (IRB) approval from Emory University School of Medicine to conduct a Phase 1b human challenge study using CDI-988, aimed at preventing and treating norovirus infections. This study will evaluate the safety and efficacy of CDI-988 in healthy volunteers, marking a significant step in the development of this therapeutic candidate. IRB approval for a Phase 1b study indicates a significant advancement in the clinical development of CDI-988, which could impact the company's future performance and market position.

Cocrystal Pharma, Inc. announced the commencement of a Phase 1b Norovirus Challenge Study for its drug CDI-988, scheduled to begin in the first quarter of 2026. This study aims to evaluate the safety and efficacy of CDI-988 in healthy volunteers exposed to norovirus, a leading cause of gastroenteritis. The company is focused on developing antiviral therapeutics and believes this study will provide valuable insights into the drug's potential. The initiation of a Phase 1b study for CDI-988 could significantly impact Cocrystal's future performance and investor sentiment regarding its antiviral pipeline.

Cocrystal Pharma, Inc. reported its financial results for the third quarter of 2025, highlighting advancements in its antiviral drug-development programs. The company provided updates on its ongoing projects and financial performance, indicating progress in its research initiatives and potential future product launches. Significant advancements in antiviral drug development could alter the company's trajectory and investor sentiment.

Cocrystal Pharma, Inc. announced that insiders purchased $1.03 million in a private placement priced at-the-market under Nasdaq rules. This move indicates confidence from company insiders in the firm's future prospects and financial health. Insider purchases can signal confidence in the company's future, potentially influencing market sentiment and financial performance.

Cocrystal Pharma, Inc. has been awarded a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to further develop its influenza inhibitor program. This funding will support the advancement of the company's antiviral therapies aimed at treating influenza, potentially enhancing its product pipeline and market position in the pharmaceutical industry. The NIH SBIR award is a significant boost for Cocrystal Pharma's influenza inhibitor program, likely impacting its future product development and market competitiveness.

Cocrystal Pharma, Inc. (COCP) presented its CDI-988 program at the Calicivirus Conference, highlighting its potential in treating viral infections. Additionally, the company announced a direct offering that could raise up to $13 million, aimed at supporting its ongoing research and development efforts. The direct offering and the showcasing of CDI-988 at a significant conference indicate strategic moves that could enhance the company's financial position and product pipeline.

Cocrystal Pharma, Inc. (COCP) presented its CDI-988 program at the Calicivirus Conference, highlighting advancements in its antiviral research. Additionally, the company announced a direct offering that could raise up to $13 million to support its ongoing projects and operations. The presentation of CDI-988 and the funding raise are expected to moderately influence Cocrystal's financial performance and product development.

Cocrystal Pharma, Inc. presented CDI-988, the first oral antiviral in development for norovirus infection, at the International Calicivirus Conference. This innovative treatment aims to address a significant unmet medical need, as norovirus is a leading cause of gastroenteritis worldwide. The presentation highlighted the drug's potential efficacy and safety profile, marking a significant milestone in the company's antiviral pipeline. The development of CDI-988 represents a significant strategic move that could enhance Cocrystal Pharma's market position and investor sentiment.

Cocrystal Pharma, Inc. (COCP) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and investor interest. The company's recent developments and market movements have contributed to its visibility among investors, indicating potential shifts in market sentiment and engagement with its stock. Increased trading activity suggests a moderate influence on market sentiment and investor interest, but does not indicate a fundamental change in the company's trajectory.

Cocrystal Pharma, Inc. has announced a registered direct offering of up to $13 million, priced at-the-market under Nasdaq rules. The offering is expected to provide the company with additional capital to support its ongoing development programs and operational needs. The capital raise may enhance financial flexibility and support product development, but its overall impact on the company's trajectory is expected to be limited.

Cocrystal Pharma, Inc. has received FDA IND clearance to conduct a challenge study for CDI-988, an oral broad-spectrum protease inhibitor aimed at preventing and treating norovirus. This marks a significant step towards developing a potential first antiviral treatment for this virus, which currently lacks effective therapies. FDA clearance for a challenge study indicates a significant advancement in Cocrystal's product development pipeline and potential market impact.

Cocrystal Pharma, Inc. (COCP) is set to initiate a Norovirus challenge study in the fourth quarter of 2025. This study aims to evaluate the efficacy of its antiviral drug candidate against Norovirus, a significant cause of gastroenteritis. The company is focused on advancing its clinical programs and addressing unmet medical needs in infectious diseases. The initiation of a Norovirus challenge study represents a significant strategic move that could enhance Cocrystal's product pipeline and market position.

Cocrystal Pharma, Inc. reported its financial results for the second quarter of 2025, highlighting progress in its antiviral drug-development programs. The company provided updates on its pipeline, emphasizing advancements in treatments targeting viral infections. Financial metrics showed a focus on research and development investments, with ongoing efforts to bring innovative therapies to market. Cocrystal remains committed to addressing unmet medical needs in the antiviral space. Significant advancements in antiviral drug development could alter the company's trajectory and investor sentiment.

Cocrystal Pharma, Inc. presented Phase 1 results for its pan-viral inhibitor CDI-988 at a Department of Defense medical conference. The data demonstrated the drug's potential effectiveness against various viral infections, highlighting its promise in addressing unmet medical needs. The company aims to advance CDI-988 through further clinical trials, focusing on its safety and efficacy. The promising Phase 1 results for CDI-988 could significantly impact Cocrystal Pharma's future product pipeline and market position.

Cocrystal Pharma, Inc. announced that its first-in-class norovirus protease inhibitor CDI-988 will be presented at the 9th International Calicivirus Conference in September 2025. Dr. Sam Lee will discuss the Phase 1 study results, highlighting CDI-988's potential as a treatment for norovirus, which currently has no approved antiviral therapies. The drug was developed using Cocrystal's proprietary technology and shows broad-spectrum activity against noroviruses and coronaviruses. The conference aims to unite experts in calicivirus research to foster collaboration and discuss advancements in the field. The presentation of CDI-988 data at a major conference could significantly influence investor sentiment and the company's future trajectory in antiviral therapeutics.